美国食品和药物管理局批准使用松格丁尼布治疗HER2突变肺癌的成年人,该药物反应率为75%. The FDA approves zongertinib for adults with HER2-mutated lung cancer, showing a 75% response rate.

FDA 已加速批准 zongertinib （Hernexeos） 用于患有某些类型的具有 HER2 突变且既往接受过治疗的非小细胞肺癌 （NSCLC） 成人。 The FDA has granted accelerated approval to zongertinib (Hernexeos) for adults with certain types of non-small cell lung cancer (NSCLC) that have HER2 mutations and who have received prior treatment. 该药物在临床试验中的总体反应率为75%,为患有这种病症的病人提供了新的定向治疗选择。 The drug showed a 75% overall response rate in clinical trials and offers a new targeted treatment option for patients with this condition. 美国食品和药物管理局还批准了一项伴随诊断测试,以确定合适的患者. The FDA also approved a companion diagnostic test to identify suitable patients.